Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

8

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014  Mike Patterson, ... of $1.6 million in Series Seed B funding ... chemical sensors for the life science, defense, intelligence, ... Capital Partners led the round and was joined ... Angels.  Said Patterson , "This round of ...
(Date:7/20/2014)... recycled, the process releases radioactive krypton and xenon gases. ... related gas radon. A new porous material called CC3 ... in Nature Materials shows how: by breathing ... , The CC3 material could be helpful in ... or air in buildings and also in recycling useful ...
(Date:7/18/2014)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it ... results on Tuesday, August 5, 2014, before the U.S. ... call and simultaneous webcast at 8:30 AM Eastern Time ... this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 ... from the ,Events and Presentations, page of Regeneron,s website ...
(Date:7/18/2014)... neutral. That is, most of the atoms in ... electrons in the outer parts of atoms equals the ... As one or more electrons are plucked away from ... positive pull from the nucleus. This enhanced pull, ... those electrons are less vulnerable to the distractions of ...
Breaking Biology Technology:Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2A noble gas cage 2A noble gas cage 3Highly charged ions 2Highly charged ions 3Highly charged ions 4
... - A new technique inspired by elegant pop-up books ... to be mass-produced by the sheet. Devised by ... enables the rapid fabrication of not just microrobots, but ... 18 layers of carbon fiber, Kapton (a plastic film), ...
... Healthcare organizations are becoming more efficient and effective ... more connected patient care environment. But to have this ... the electronic medical record (EMR) and enterprise content management ... leader in ECM for healthcare , has a ...
... A protein that has shown early promise in preventing the ... has been found in a new study to be a key ... protein biglycan needs to be present to stabilize synapses at the ... Brown University that appears in the Feb. 14, 2012, issue of ...
Cached Biology Technology:In new mass-production technique, robotic insects spring to life 2In new mass-production technique, robotic insects spring to life 3Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System 2Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System 3When nerve meets muscle, biglycan seals the deal 2
(Date:7/22/2014)... researchers in modifying properties of nanomaterials for application in ... to recent innovative studies conducted by scientists from the ... of a simple, efficient and low cost technique involving ... by Professor Sow Chorng Haur from the Department of ... the properties of two different types of materials can ...
(Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
(Date:7/22/2014)... DURHAM, N.C. In a cost-effectiveness analysis of commercial ... the drug Qsymia showed the best value for the ... loss, but was also the most expensive option tested, ... Graduate Medical School. , The findings, published in the ... important information on the health and weight-loss benefits per ...
Breaking Biology News(10 mins):NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
... to save Australia’s iconic Tasmanian devils from the deadly ... Livestock Industries’ Australian Animal Health Laboratory (AAHL), Textiles and ... to hunt down the cause of Devil Facial Tumour ... infected animals. , DFTD is infectious and ...
... markers in the DNA of people with and ... researchers to identify a common gene that appears ... disease. The finding, announced today by researchers at ... Institute, Kronos Science Laboratory and their collaborative partners, ...
... dioxide emissions, but scientists at UC Irvine have determined ... explain one-third or more of the Arctic warming primarily ... soot from tailpipes, smoke stacks and forest fires enters ... is darker than natural snow. Dark surfaces absorb sunlight ...
Cached Biology News:CSIRO scientists join fight to save 'Tassie devil' 2Research team identifies new Alzheimer's gene 2Research team identifies new Alzheimer's gene 3Dirty snow may warm Arctic as much as greenhouse gases 2
... that made the original Gene Pulser apparatus and ... has been applied in the Gene Pulser II ... design of the Gene Pulser II system has ... has the widest range of settings to target ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... Experion Pro260 reagents and supplies, ... and supplies sufficient to perform protein ... Experion automated electrophoresis system. Supplied are ... 45 microliters Pro260 stain, 60 microliters ...
... 3000 drug discovery system miniaturizes, integrates ... Using LabChip technology, the LabChip ... serial, continuous flow fashion. LabChip assays ... results exceeds what is achievable in ...
Biology Products: